Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 4/20 | 0.44 |
| ▸ | LTK | P29376 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.43 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 3/20 | 0.42 |
| ▸ | BCR | P11274 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.42 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.42 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2821053 | 0.84 | LTK (0.46) | LTKCDK8MAP2K1ROCK1NTRK3 | |
| SCHEMBL2818625 | 0.84 | KDR (0.48) | IKBKBLTKMAP2K1ROCK1NTRK3 | |
| SCHEMBL8401624 | 0.76 | BTK (0.54) | BTK | |
| SCHEMBL2817603 | 0.75 | GRK2 (0.50) | IKBKBMAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL2821616 | 0.73 | CSF1R (0.45) | IKBKBLIMK1MAPKAPK2MKNK1MKNK2 | |
| SCHEMBL2817394 | 0.73 | KDR (0.70) | IKBKBROCK1NTRK3NTRK2LIMK1 | |
| SCHEMBL2815922 | 0.71 | KDR (0.49) | LTKCDK8ROCK1NTRK3NTRK2 | |
| SCHEMBL2228840 | 0.69 | KDR (0.42) | LTKCDK8ROCK1NTRK3NTRK2 | |
| SCHEMBL4857909 | 0.69 | SMN1; SMN2 (0.55) | IKBKBROCK1LIMK1FYNBTK | |
| SCHEMBL1459525 | 0.69 | ABL1 (0.43) | ABL1BCRMAPK1MAP2K4MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061790-B1 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them | BAYER IP GMBH (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-7846928-B2 | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| EP-1867648-A1 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | KDR, TIE1, FLT1 | IKBKB 1240/4885LTK 511/4885CDK8 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.